Form 4: Aileron Therapeutics Director Acquires 35,000 Stock Options

Aileron Therapeutics director Manuel Aivado was granted 35,000 stock options on December 2, 2024, which will vest on December 2, 2025.

Summary

• Manuel Aivado, a director at Aileron Therapeutics, was granted 35,000 stock options on December 2, 2024.
• The exercise price of these options is $2.85 per share.
• The options will vest in full on December 2, 2025.
• The options expire on December 1, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction of stock options being granted to a director, which is generally viewed as a positive sign of alignment between management and shareholders. There is no indication of any negative or unusual activity.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting period of one year may encourage the director to focus on long-term value creation.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for compensating directors in the biotechnology industry.
• The vesting period of one year is typical for such grants, encouraging long-term focus.
• The exercise price of $2.85 is a specific value for this grant and would need to be compared to other grants to determine if it is standard.

Stakeholder Impact

• The stock option grant may be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates

Keywords

stock options, insider trading, director, Aileron Therapeutics, ALRN, equity, vesting